Live

Stocks are rallying as Trump eased fears over China tariffs and Powell. See the latest.

NasdaqCM - Nasdaq Real Time Price USD

Protagenic Therapeutics, Inc. (PTIXW)

0.0044

-0.0001

(-2.22%)

As of 10:01:00 AM EDT. Market Open.

Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today that on November 4, 2024 it closed its previously announced ...

ACCESS Newswire 5 months ago

PTIX

PTIXW
-2.22%
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it has entered into a purchase agreement (the "Purchase ...

ACCESS Newswire 5 months ago

PTIX

PTIXW
-2.22%
Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders

No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to Commence Investor Call Scheduled for today, Wednesday, May 22, at 10:00 am ET to Discuss Potential Impact on PTSD, Depression, Anxiety, Addiction, and ...

ACCESS Newswire 10 months ago

PTIX

PTIXW
-2.22%
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial

NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion of its Phase 1 trial involving PT00114, its synthetic ...

ACCESS Newswire 11 months ago

PTIX

PTIXW
-2.22%